Advice

following a full submission:

clostridium botulinum neurotoxin type A (Xeomin®) is accepted for use within NHSScotland.

Indication under review: for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults.

Clostridium botulinum neurotoxin type A improved unstimulated saliva flow rate and the Global Impression of Change Scale compared with placebo.

Medicine details

Medicine name:
clostridium botulinum neurotoxin type A (Xeomin)
SMC ID:
SMC2212
Indication:

Adult patients with chronic sialorrhoea due to neurological conditions.

Pharmaceutical company
Merz Pharma UK Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Accepted
Date advice published:
11 November 2019